<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151299">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01130493</url>
  </required_header>
  <id_info>
    <org_study_id>IPX066-B09-06</org_study_id>
    <nct_id>NCT01130493</nct_id>
  </id_info>
  <brief_title>A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066</brief_title>
  <acronym>CLE with OLE</acronym>
  <official_title>A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IMPAX Laboratories, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IMPAX Laboratories, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to compare the efficacy of IPX066 and CLE in subjects with advanced
      Parkinson's disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, double-dummy, 2 treatment, 2-period crossover study
      followed by an open-label extension study period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Parkinson's Disease Patient Diary</measure>
    <time_frame>Weeks 1-11</time_frame>
    <description>A subject-completed diary of Parkinson's Disease(PD) symptoms.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>IPX066</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IPX066</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbidopa/Levodopa/Entacapone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carbidopa/Levodopa/Entacapone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPX066</intervention_name>
    <description>IPX066</description>
    <arm_group_label>IPX066</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbidopa/Levodopa/Entacapone</intervention_name>
    <description>Carbidopa/Levodopa/Entacapone</description>
    <arm_group_label>Carbidopa/Levodopa/Entacapone</arm_group_label>
    <other_name>Stalevo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosed with idiopathic Parkinson's Disease (PD).

          2. At least 30 years old at the time of PD diagnosis.

          3. Currently being treated with carbidopa/levodopa/entacapone (CLE) and on a stable
             regimen of conventional LD for at least 4 weeks and:

               -  Requiring a total daily levodopa (LD) dose of at least 400 mg

               -  Having a minimum dosing frequency of four times per day.

               -  Individual CD-LD or CLE doses that contain an LD dose which is a multiple of 50
                  mg.

          4. Able to differentiate &quot;on&quot; state from &quot;off&quot; state.

          5. Have predictable &quot;off&quot; periods.

          6. Amantadine, anticholinergics, selective monoamine oxidase (MAO) type B inhibitors
             (e.g., selegiline, rasagiline) or dopamine agonists are allowed as long as the doses
             and regimens have been stable for at least 4 weeks prior to Screening and the therapy
             is intended to be constant throughout the course of the study.

          7. Agrees to use a medically acceptable method of contraception throughout the study and
             for 1 month afterward.

        Exclusion Criteria:

          1. Diagnosed with atypical Parkinsonism or any known secondary Parkinsonian syndrome.

          2. Nonresponsive to LD therapy.

          3. Prior functional neurosurgical treatment for PD (e.g., ablation or deep brain
             stimulation) or if such procedures are anticipated during study participation.

          4. Received within 4 weeks of Screening or planning to take during participation in the
             clinical study: any controlled-release LD product, tolcapone, apomorphine,
             nonselective MAO inhibitors, or antipsychotics including neuroleptic agents for the
             purpose of treating psychosis or bipolar disorder.

          5. Allergy or hypersensitivity to CD, LD, entacapone, riboflavin, Yellow Dye #5
             (tartrazine), citrus fruit or grape juice.

          6. History of or currently active psychosis.

          7. Active or prior medical conditions such as peptic ulcers or prior surgical (e.g.,
             bowel) procedures that would interfere with LD absorption.

          8. Active or history of narrow-angle glaucoma.

          9. History of malignant melanoma or a suspicious undiagnosed skin lesion.

         10. History of myocardial infarction with residual atrial, nodal, or ventricular
             arrhythmias, upper gastrointestinal hemorrhage, or neuroleptic malignant syndrome or
             nontraumatic rhabdomyolysis.

         11. Received any investigational medications during the 4 weeks prior to Screening.

         12. Unable to swallow large pills (e.g., large vitamin pills).

         13. Pregnant or breastfeeding.

         14. Subjects who are unable to complete a symptom diary.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Impax Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Impax Laboratories, Inc., acting through its Impax Pharmaceuticals Division (Impax)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Margolin Brain Institute</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Parkinson's Institute in Sunnyvale</name>
      <address>
        <city>Sunnyvale</city>
        <state>California</state>
        <zip>94085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UM Movement Disorders Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlotte Neurological Services</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33980</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USF Parkinson's and Movement Disorders Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quest Research Institute</name>
      <address>
        <city>Bingham Farms</city>
        <state>Michigan</state>
        <zip>48025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Systems</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkinson's Disease and Movement Disorders Center of Long Island</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kingston Neurological Associates</name>
      <address>
        <city>Kingston</city>
        <state>New York</state>
        <zip>12401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Neurology, Inc</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Neurological Associates</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Booth Gardner Parkinson's Care Center</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Gabriel Montpied-Service de Neurologie A-</name>
      <address>
        <city>Clermont-Ferrand Cedex 1</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de neurologie-Hôpital de la Timone-</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Neurologie, Psychiatrie und Psychotherapie Achim</name>
      <address>
        <city>Achim</city>
        <zip>28832</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dres. Bitter/Schumann</name>
      <address>
        <city>Bochum</city>
        <zip>44805</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der Technischen Universität München</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Neurologie, Stadtroda</name>
      <address>
        <city>Stadtroda</city>
        <zip>07646</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RKU, Neurologische Klinik der Universität Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Casa di Cura Villa Margherita</name>
      <address>
        <city>Arcugnano</city>
        <zip>36057</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Raffaele Cassino, San Raffaele Cassino,</name>
      <address>
        <city>Cassino</city>
        <zip>03043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Oncologia e Neuroscienze, Università G. D'Annunzio</name>
      <address>
        <city>Chieti</city>
        <zip>66013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale della Misericordia</name>
      <address>
        <city>Grosseto</city>
        <zip>58100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS San Raffaele Pisana</name>
      <address>
        <city>Roma</city>
        <zip>163</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 27, 2013</lastchanged_date>
  <firstreceived_date>May 24, 2010</firstreceived_date>
  <firstreceived_results_disposition_date>September 27, 2013</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carbidopa, levodopa drug combination</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Entacapone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
